Seòmar agus comataidhean

While the Scottish Government remains committed to its vision for an integrated and community-based hearing service in Scotland, re-phasing of funding has meant that not all the challenges we are facing will be addressed in a single budget and therefore there is no community hearing service in operation at this time.

While our response to the Independent Review of Audiology is implemented, we will continue to work with the NHS, Third Sector and private providers to identify and cost an appropriate model of community care for any future service reform, and ensure that the voices of those with lived experience inform this work.

The Scottish Government is actively working with partners to establish the Investment Zone for the North East region. There is a jointly agreed and delivered Gateway process for the Investment Zone to follow through to delivery. This is currently underway, and it is anticipated that the Investment Zone will be established and operational later this year.

The Scottish Government does not intend to publish the legal or other advice obtained by NatureScot regarding which areas of land should be covered by a 16AA licence under the Wildlife Management and Muirburn (Scotland) Act 2024.

It is for NatureScot to determine whether to publish this advice.

Firstly, let me put on record again, my deepest condolences to the family of Mr Bayoh.

Following their request for an extension of the terms of reference for the Sheku Bayoh Public Inquiry, to include both the initial prosecutorial decisions and the Victim’s Right of Review, I have undertaken extensive consultation with all core participants to the Inquiry and their legal representatives. I have also discussed the application for extension with the Chair of the Inquiry, who is a statutory consultee under section 5(4) of the Inquiries Act 2005 (“the 2005 Act”).

After careful consideration, I have decided not to grant the request. I understand that Mr Bayoh’s family will be disappointed by my decision.

As set out in legislation, I may amend the terms of reference if I consider the public interest requires this. This request to extend the Terms of Reference was formally made on 4 September, over four years after the current Terms of Reference were announced, and as the Inquiry was nearing the final module of evidential hearings and concluding statements. It is in the public interest for the Inquiry to come to a conclusion promptly and for its recommendations to be implemented as swiftly as possible.

Under the 2005 Act, an Inquiry is not permitted to determine or rule on civil or criminal liability. Prosecutorial decisions are a matter for the Crown and the Solicitor General has committed to assessing any new evidence which is brought to light by the Inquiry, having reserved the right to prosecute any of the individuals involved in future.

I am confident the current terms of reference are sufficiently broad to allow the Chair to present a substantial report with detailed findings and recommendations – including on the investigation and the extent to which Mr Bayoh’s actual or perceived race was a factor.

In April 2023, the Chief Pharmaceutical Officer (CPO) announced an Independent Medicines Homecare Review in response to reports of failings in the standards of care provided across Scotland and the increasing demand for medicines homecare provision.

The CPO will be publishing the Homecare Medicines Review before the end of March. In terms of next steps, the CPO has met with NHS National Procurement to discuss what actions can be taken forward within their remit and what actions require further consideration through a task and finish group. The group will be established shortly and will be chaired by a Director of Pharmacy and a Director of Nursing. The Group will help to outline the next steps and timescales to delivery.

While the Scottish Government remains committed to its vision for an integrated and community-based hearing service in Scotland, re-phasing of funding has meant that not all the challenges we are facing will be addressed in a single budget and therefore there is no community hearing service in operation at this time.

While our response to the Independent Review of Audiology is implemented, we will continue to work with the NHS, Third Sector and private providers to identify and cost an appropriate model of community care for any future service reform, and ensure that the voices of those with lived experience inform this work.

A progress report on the Fair Work Action Plan (FWAP) was included in the National Strategy for Economic Transformation (NSET) annual report in 2024. It is anticipated that the next FWAP progress report will be published alongside the third NSET annual report later this year. This will provide updates on the FWAP outcome progress indicators, in line with the approach set out in the Fair Work Evidence Plan.

Oversight of the FWAP is provided by the Fair Work Oversight Group who meet biannually to consider progress against outcomes.

While employment law is reserved, the Scottish Government is using the levers we have to strengthen effective voice and collective bargaining, with a focus on low-paid and precarious sectors, including through our flagship Fair Work First policy. Work is ongoing through the Fair Work in Social Care Group to finalise an approach to sectoral bargaining for the adult social care sector. Although complex, once developed and introduced, this will encourage improvements in the terms and conditions of the social care workforce, specific to the roles and responsibilities across this sector.

The Scottish Government is committed to promoting collective bargaining and, despite financial constraints, we continue to provide funding and support to trade unions, recognising their role in advancing fair work across Scotland.

The Scottish Medicines Consortium (SMC) has not yet received a submission from the manufacturing company, Vertex, for exagamglogene autotemcel (Casgevy®) for the treatment of sickle cell disease (SCD).

The Chief Pharmaceutical Officer (CPO) and the SMC have engaged regularly with the marketing authorisation holder, Vertex Pharmaceuticals, on the SMC’s process for assessing the clinical and cost-effectiveness of exagamglogene autotemcel (Casgevy®) for use in the SCD indication in the NHS in Scotland. The SMC would welcome a submission from Vertex for Casgevy® in the SCD indication at any time.

When leasing agricultural land, the Scottish Government endeavours to use the Farming Opportunities for New Entrants (FONE) Group scoring matrix wherever possible.

The Cass Review only considered services offered by NHS England, and the report’s 32 recommendations are made to NHS England. As such, NHS England holds responsibility for implementing these recommendations.

The Scottish Government did, however, commit to closely consider the Review’s findings in the context of NHS Scotland services. Accordingly, the Chief Medical Officer for Scotland convened a multidisciplinary team to consider the Review’s recommendations and how they might be applicable to Scotland, which published its findings on 5 July 2024. The Scottish Government has accepted this report and its recommendations.

A “Task and Finish” group, supported by the Scottish Government’s Chief Operating Officer’s Directorate, has now been convened to design a sustainable model for young people’s gender identity services, and the work of this group will be shaped by the multidisciplinary team’s recommendations. Additionally, as recommended by the report, NHS Greater Glasgow and Clyde ended self-referrals to the Sandyford Gender Identity Clinic in August 2024, and the health board is taking forward work to move young people’s gender identity services into a paediatric clinical setting.